Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Rated “Moderate Buy” by Wall Street Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO) has been assigned a consensus rating of “Moderate Buy” from the twenty-six ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $654.05.

A number of research firms have recently weighed in on TMO. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. TD Cowen increased their target price on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Finally, CLSA started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 target price for the company.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $15,501,867,000. Corient Private Wealth LP purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $382,547,000. Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $1,974,561,000. Bank of America Corp DE acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth about $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after buying an additional 22,827 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 1.2%

Thermo Fisher Scientific stock opened at $687.72 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market cap of $254.28 billion, a P/E ratio of 28.51, a P/E/G ratio of 2.83 and a beta of 0.87. The business has a fifty day moving average of $640.60 and a two-hundred day moving average of $551.25. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $704.00.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts forecast that Thermo Fisher Scientific will post 25.13 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.